MAPT and Alzheimer disease: GSK‐3β is activated in the brains of AD patients and the mouse models (Ali & Kim, 2015; Hooper, Killick, & Lovestone, 2008), overexpression of GSK‐3β in adult mouse brain induces tau hyperphosphorylation and consequently neurodegeneration (Lucas et al., 2001).